Denali Therapeutics Inc (NAS:DNLI)
$ 24.94 -0.75 (-2.92%) Market Cap: 3.99 Bil Enterprise Value: 3.31 Bil PE Ratio: 0 PB Ratio: 4.77 GF Score: 33/100

Denali Therapeutics Inc Presentation at WORLDSymposium™ Transcript

Feb 05, 2026 / 08:30PM GMT
Release Date Price: $20.02 (-5.92%)

Feb 05, 2026 / 08:30PM GMT
Presentation at WORLDSymposiumâ¢
Feb 05, 2026 / 08:30PM GMT

=====================
Corporate Participants
=====================
* Ryan Watts
Denali Therapeutics Inc - President, Chief Executive Officer, Director
* Peter Chin
Denali Therapeutics Inc - Acting Chief Medical Officer, Head - Development
* Joe Lewcock
Denali Therapeutics Inc - Chief Scientific Officer

=====================
Conference Call Participants
=====================
* Andrew Tsai
Jefferies LLC - Analyst
* Salveen Richter
Goldman Sachs Group Inc - Analyst
* Mayank Mamtani
B. Riley Securities Holdings Inc - Analyst
* Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst
* Michael Yee
UBS AG - Analyst
* Myles Minter
William Blair Capital Partners - Analyst
* Ananda Ghosh
H C Wainwright & Co LLC (Pre-Merger) - Equity Analyst
* Joseph Thome
Cowen and Company LLC - Analyst
* Marc Goodman
Leerink Partners LLC - Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot